# Palvella Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/palvella-therapeutics

- Industry: Biotechnology
- Headquarters: Wayne, US
- Website: www.palvellatx.com
- Total disclosed funding: $55M
- Latest round: Series D (Dec 16, 2022)
- Investors on record: 11

## About

Founded in 2015, and based in Wayne, US, Palvella Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare genetic skin diseases with no FDA-approved treatments. In October 2025, Palvella Therapeutics, Inc. received an undisclosed amount of Grant funding from new investor U.S. Food and Drug Administration. The deal was part of a larger USD 2.6 million non-dilutive grant funding.

## Funding rounds

- Series D, Dec 16, 2022, $9.7M — BioAdvance, BVF Partners, Gore Range Capital, Agent Capital, Samsara BioCapital, Petrichor, Nolan Capital
- Series C, May 28, 2020, $45M — Adams Street Partners, BioAdvance, CAM Capital, Ligand Pharmaceuticals, Inc., BVF Partners, Agent Capital, Samsara BioCapital, Opaleye Management, Nolan Capital

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series C
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series C, Series D
- CAM Capital — Series C
- Ligand Pharmaceuticals, Inc. — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C, Series D
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series C, Series D
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C, Series D
- Opaleye Management — Series C
- Nolan Capital — Series C, Series D
- Gore Range Capital (https://capitalatlas.ai/funds/gore-range-capital) — Series D
- Petrichor (https://capitalatlas.ai/funds/petrichor) — Series D